The Modulation of Radiosensitivity by Combined Treatment of Selective COX-2 Inhibitor, NS 398 and EGF Receptor Blocker AG 1478 in HeLa Cell Line

선택적 COX-2 억제제 NS 398과 EGF 수용체 차단제 AG 1478의 복합투여가 HeLa 세포주의 방사선 감수성에 미치는 영향

  • Youn Seon Min (Department of Radiation Oncology, Eulji University School of Medicine) ;
  • Oh Young Kee (Department of Radiation Oncology, Eulji University School of Medicine) ;
  • Kim Joo Heon (Department of Pathology, Eulji University College of Medicine) ;
  • Park Mi Ja (Department of Pathology, Eulji University College of Medicine) ;
  • Seong In Ock (Department of Pathology, Eulji University College of Medicine) ;
  • Kang Kimun (Department of Radiation Oncology, Gyeongsang National University) ;
  • Chai Gyuyong (Department of Radiation Oncology, Gyeongsang National University)
  • 윤선민 (을지의과대학교 방사선종양학교실) ;
  • 오영기 (을지의과대학교 방사선종양학교실) ;
  • 김주헌 (을지의과대학교 해부병리학교실) ;
  • 박미자 (을지의과대학교 해부병리학교실) ;
  • 성인옥 (을지의과대학교 해부병리학교실) ;
  • 강기문 (경상대학교 의과대학 방사선종양학교실) ;
  • 채규영 (경상대학교 의과대학 방사선종양학교실)
  • Published : 2005.03.01

Abstract

Purpose : Selective inhibition of multiple molecular targets may improve the antitumor activity of radiation. Two specific inhibitors of selective cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) were combined with radiation on the HeLa cell line. To investigate cooperative mechanism with selective COX-2 inhibitor and EGFR blocker, in vitro experiments were done. Materials and Methods : Antitumor effect was obtained by growth inhibition and apoptosis analysis by annexin V-Flous method. Radiation modulation effects were determined by the clonogenic cell survival assay. Surviving fractions at 2 Gy ($SF_2$) and dose enhancement ratio at a surviving fraction of 0.25 were evaluated. To investigate the mechanism of the modulation of radiosensitivity, the cell cycle analyses were done by flow cytometry. The bcl-2 and bax expressions were analyzed by western blot. Results : A cooperative effect were observed on the apoptosis of the HeLa ceil line when combination of the two drugs, AG 1478 and NS 398 with radiation at the lowest doses, apoptosis of $22.70\%$ compare with combination of the one drug with radiation, apoptosis of $8.49\%$. In cell cycle analysis, accumulation of cell on $G_0/G_l$ phase and decrement of S phase fraction was observed from 24 hours to 72 hours after treatment with radiation, AG 1478 and NS 398. The combination of NS 398 and AG 1478 enhanced radiosensitivity on a concentration-dependent manner in HeLa cells with dose enhancement ratios of 3.00 and $SF_2$ of 0.12 but the combination of one drug with radiation was not enhanced radlosensitivity with dose enhancement ratios of 1.12 and SF2 of 0.68 (p=0.005). The expression levels of bcl-2 and bax were reduced when combined with AG 1478 and NS 398. Conclusion : Our results indicate that the selective COX-2 inhibitor and EGFR blocker combined with radiation have potential additive or cooperative effects on radiation treatment and may act through various mechanisms including direct inhibition of tumor cell proliferation, suppression of tumor cell cycle progression and inhibition of anti-apoptotic proteins.

목적 : 분자 표적의 선택적 억제가 방사선 세포 살상 효과를 증진시키는 것으로 알려져 있으므로 선택적 COX-2 억제제와 EGF 수용체 차단제를 HeLa 세포주에 처리한 후 방사선 효과의 상승작용을 알아보고자 하였다. 대상 및 방법 : 자궁경부암 세포주인 HeLa세포에서 EGF 수용체 차단제 AG 1478, 선택적 COX-2 억제제 NS 398과 방사선을 복합 투여하여 세포성장 억제 분석(cell graph inhibition assay)과 세포사멸 분석(apoptosis assay)을 시행하였고, 방사선 감수성 변화를 살펴보기 위해 세포생존 분석(clonogenic survival assay)을 시행하였다. 방사선 감수성 인자로는 2 Gy에서의 세포생존분획($SF_2$)과 linear-quadratic model을 이용한 dose enhancement ratio (DER)를 사용하였다. 방사선 감수성에 대한 작용기전 분석을 위해 flow cytometry로 세포주기 분석(cell cycle analysls)을 시행하였고, western blot 분석을 통하여 bcl-2와 bax 단백질의 발현 변화를 살펴보았다. 결과 : HeLa세포에 NS 398과 AG 1478을 방사선과 함께 복합 투여한 실험 군에서 세포사멸 정도가 가장 높게 나타났다($8.49\%$ vs. $22.70\%$). 세포주기 분석 결과, 방사선과 복합 약물 처리군에서 $G_0/G_l$ 세포주기 정체와 5 세포 분획 소실이 나타났으며 이러한 변화는 72시간 이후까지 지속되었다 세포생존 분석 결과로는 방사선과 AG 1478군에서 $SF_{2}0.68{\pm}0.07$, DER 1.12를 보인 반면, 방사선과 복합약물처리군에서는 $SF_{2}0.12{\pm}0.01,\;DER\;3.00$으로 나타났다. Western blot분석에서는 방사선과 복합약물처리군에서 bcl-2와 bax 단백질 발현이 모두 감소하는 양상을 보였다. 결론 : 신호전달 체계를 억제하는 분자 표적 약제인 선택적 COX-2 억제제와 EGF 수용체 차단제를 방사선과 복합투여함으로써 HeLa세포의 방사선 감수성이 증가됨을 확인하였다.

Keywords

References

  1. Kim GE. Targeted therapies and radiation for the treatment of head and neck cancer. J Korean Soc Ther Radiol Oncol 2004;22;70-90
  2. Park HS, Lee NS. Molecular targeted therapy in cancer. J Kor Med Assoc 2003;I47:542-548
  3. David R, Barb H, Paul A, et al. Targeted therapies for nonsmall-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 2004;59:27-38 https://doi.org/10.1016/j.ijrobp.2004.01.054
  4. Herbert RS, Maddox AM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-3824 https://doi.org/10.1200/JCO.2002.03.038
  5. Hidalgo M, Siu LL, Nemunaitis J. Phase I and pharmacological study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279 https://doi.org/10.1200/JCO.2001.19.13.3267
  6. Baselag J, Reschin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-4302 https://doi.org/10.1200/JCO.2002.03.100
  7. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepideral growth factor monoclonal antibody EMD 7200 in patients with advanced solid tumors that express the epidermal growth factor. J Clin Oncol 2004;22:175-184 https://doi.org/10.1200/JCO.2004.05.114
  8. Matar P, Rojo R, Guzman M. Combined anti-epidermal growth factor receptor (EGFR) treatment with a tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) and monoclonal antibody (IMC-C225) Evidence of synergy. Proc AACR 2003;44:918
  9. Cataldo B, Roberto B, Giampaolo T, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase. Clin Cancer Res 2000;6:4343-4350
  10. Giralt P.M, Harari K, Ang N, et al. A phase III study of high dose radiotherapy with or without cetuximab in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Radiat Oncol 2004;73(Suppl 1):217
  11. Baselga J, Herbst R, Lorusso P, et al. Continuous administration of ZD 1839 (Iressa), a novel oral epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability (Abst.686). Proc Am Soc Clin Oncol 2000;19:177a
  12. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in nonsmall-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-3825 https://doi.org/10.1200/JCO.2002.03.038
  13. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-1594 https://doi.org/10.1172/JCI9621
  14. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochemi 2000;69:145-182 https://doi.org/10.1146/annurev.biochem.69.1.145
  15. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-7916 https://doi.org/10.1038/sj.onc.1203286
  16. Palayoor ST, Bump EA, Calderwood SK, et al. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res 1998;4:763-771
  17. Pyo H, Choy H, Amorino GP, et al. Selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001;7:2998-3005
  18. Weimin L, Yuhchyau C, Wei W, et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 2003;26:100-103 https://doi.org/10.1097/00000421-200308000-00031
  19. Nazanin A, Lynn H, Melanie S, et al. NS 398 radiosensitizes and HNSCC cell line by possibly inhibiting radiationinduced expression of COX-2. Int J Radiat Oncol Biol Phys 2003;5:1405-1412
  20. Kaplan EL, Meir P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481 https://doi.org/10.2307/2281868
  21. Raben D, Bianco C, Milas L, et al. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? Semin Radiat Oncol 2004;14:139-152 https://doi.org/10.1053/j.semradonc.2003.12.009
  22. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-1140 https://doi.org/10.1016/S0959-8049(02)00013-8
  23. Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, et al. Combined targeted inhibition of bcl-2, bcl-xL, epidermal growth factor receptor, and protein kinase a type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin Cancer Res 2003;9:866-871
  24. Huang SM, Jonathan M, Bock M, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-1940
  25. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-2707
  26. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damaged repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-2174
  27. Eiko NM, Kathryn A, Mason M, et al. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 2004;58:369-375 https://doi.org/10.1016/j.ijrobp.2003.09.061
  28. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non small lung cancer. J Clin Oncol 2003;21:2645-2650 https://doi.org/10.1200/JCO.2003.07.127
  29. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002:;62:4307-4315
  30. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science (Wash. DC) 1995;267:1782-788 https://doi.org/10.1126/science.7892601
  31. Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002;1:507-514
  32. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-1292 https://doi.org/10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X
  33. Jeong SJ, Jeong MH, Jang JY, et al. Regulatory mechanism of radiation induced cancer cell death by the change of cell cycle. J Korean Soc Ther Radiol Oncol 2003;21:306-314
  34. Agarwal ML, Agarwal M, Taylor WR, Stark GR. P53 control both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblast. Proc Natl Acad Sci USA 1995;92:8493-8497 https://doi.org/10.1073/pnas.92.18.8493
  35. Grandis J, Tweardy D. Elevated levels of transforming growth factor and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-3584
  36. Kim KY, Seol JY, Jeon GA, Nam MJ. The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell. Cancer Letters 2003;183:157-166 https://doi.org/10.1016/S0304-3835(02)00519-0
  37. Lee HS, Choi YM, Kwon JC, et al. A novel chenodeoxycholic derivative HS-1200 enhances radiation-induced apoptosis in human MCF-7 breast cancer cells. J Korean Soc Ther Radiol Oncol 2004;22:145-154
  38. Jieying X, Jun C, Garry C, et al. Antisense BAG-1 sensitizes HeLa cells to apoptosis by multiple pathways. BBRC 2003;312:585-591
  39. Denis S, Armine V, Olga Yu, et al. 'Wages of fear': transient threefold decrease in intracellular ATP level impose apoptosis. Biochem Biophysic Acta 2004;1658:141-147 https://doi.org/10.1016/j.bbabio.2004.05.007